Drug versus vaccine investment: a modelled comparison of economic incentives

Cost Effectiveness and Resource Allocation

Jasper Huels¹  Stéphane A Régnier¹ 

[1]Novartis Vaccines & Diagnostics AG, Lichstrasse 35, Basel, 4056, Switzerland

关键词: Net present value;    Investment;    Research and development;    Drugs;    Vaccines;    Incentives;   

Others  :  817786
DOI  :  10.1186/1478-7547-11-23

 received in 2013-02-20, accepted in 2013-09-04,  发布年份 2013

【 摘 要 】

Background

Investment by manufacturers in research and development of vaccines is relatively low compared with that of pharmaceuticals. If current evaluation technologies favour drugs over vaccines, then the vaccines market becomes relatively less attractive to manufacturers.

Methods

We developed a mathematical model simulating the decision-making process of regulators and payers, in order to understand manufacturers’ economic incentives to invest in vaccines rather than curative treatments. We analysed the objectives and strategies of manufacturers and payers when considering investment in technologies to combat a disease that affects children, and the interactions between them.

Results

The model confirmed that, for rare diseases, the economically justifiable prices of vaccines could be substantially lower than drug prices, and that, for diseases spread across multiple cohorts, the revenues derived from vaccinating one cohort per year (routine vaccination) could be substantially lower than those generated by treating sick individuals.

Conclusions

Manufacturers may see higher incentives to invest in curative treatments rather than in routine vaccines. To encourage investment in vaccines, health authorities could potentially revise their incentive schemes by: (1) committing to vaccinate all susceptible cohorts in the first year (catch-up campaign); (2) choosing a long-term horizon for health technology evaluation; (3) committing higher budgets for vaccines than for treatments; and (4) taking into account all intangible values derived from vaccines.

【 授权许可】

   
2013 Régnier and Huels; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

【 参考文献 】

• [1]Berman S, Giffin RB: Global perspectives on vaccine financing. Expert Rev Vaccines 2004, 3:557-562.
• [2]IMS Institute for Healthcare Informatics: Biopharma Forecasts & Trends, April 20, 2010: IMS forecasts global pharmaceutical market growth of 5-8% annually through 2014; maintains expectations of 4-6% growth in 2010. Parsippany, NJ: IMS Institute for Healthcare Informatics; [http://www.theimsinstitute.org webcite]
• [3]Sahoo A: Vaccines 2011: Market analysis, key players and critical trends in a fast-changing industry. Rockville, MD: Kalorama Information; 2011.
• [4]Masignani V, Lattanzi M, Rappuoli R: The value of vaccines. Vaccine 2003, 21(Suppl 2):S110-S113.
• [5]Rappuoli R, Miller HI, Falkow S: Medicine. The intangible value of vaccination. Science 2002, 297:937-939.
• [6]Whitehead P, Pasternak A: Lessons learned: new procurement strategies for vaccines. Final report to the GAVI Board. Chicago, IL: Mercer Management Consulting, Inc.; 2002.
• [7]Beutels P, Scuffham PA, MacIntyre CR: Funding of drugs: do vaccines warrant a different approach? Lancet Infect Dis 2008, 8:727-733.
• [8]Baumann M: What’s behind vaccine shortages? NCPA Brief Analysis No. 655. National Center for Policy Analysis: Dallas, TX; 2009.
• [9]International Society for Pharmacoeconomics and Outcome Research (ISPOR): ISPOR Global Health Care Systems Roadmap. Lawrenceville, NJ: ISPOR; [http://www.ispor.org/htaroadmaps/ webcite]
• [10]Walker D, Beutels P, WHO Initiative for Vaccine Research: WHO guide for standardization of economic evaluations of immunization programmes. Geneva: World Health Organization; 2008.
• [11]Greuel JM: Pharma and biotech: is it possible to keep growing? Pharma Focus Asia 2008, 6-9. http://www.pharmafocusasia.com/strategy/pharma_biotech_growth.htm webcite
• [12]Committee on the Evaluation of Vaccine Purchase Financing in the United States: Financing Vaccines in the 21st Century: Assuring Access and Availability. Washington, DC: The National Academies Press; 2003.
• [13]DiMasi JA, Hansen RW, Grabowski HG: The price of innovation: new estimates of drug development costs. J Health Econ 2003, 22:151-185.
• [14]Ferrera G, Cuccia M, Mereu G, Icardi G, Bona G, Esposito S, Federico M, Messier M, Kuriyakose S, Hardt K: Booster vaccination of pre-school children with reduced-antigen-content diphtheria-tetanus-acellular pertussis-inactivated poliovirus vaccine co-administered with measles-mumps-rubella-varicella vaccine: A randomized, controlled trial in children primed according to a 2 + 1 schedule in infancy. Hum Vaccin Immunother 2012, 8:355-362.
• [15]MacLennan JM, Shackley F, Heath PT, Deeks JJ, Flamank C, Herbert M, Griffiths H, Hatzmann E, Goilav C, Moxon ER: Safety, immunogenicity, and induction of immunologic memory by a serogroup C meningococcal conjugate vaccine in infants: a randomized controlled trial. JAMA 2000, 283:2795-2801.
• [16]Christensen H, Hickman M, Edmunds WJ, Trotter CL: Introducing vaccination against serogroup B meningococcal disease: an economic and mathematical modelling study of potential impact. Vaccine 2013, 31(23):2638-2646.
• [17]JCVI interim position statement on use of Bexsero® meningococcal B vaccine in the UK. 2013. [https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/224896/JCVI_interim_statement_on_meningococcal_B_vaccination_for_web.pdf webcite]
• [18]Corey L, Nabel GJ, Dieffenbach C, Gilbert P, Haynes BF, Johnston M, Kublin J, Lane HC, Pantaleo G, Picker LJ, Fauci AS: HIV-1 vaccines and adaptive trial designs. Sci Transl Med 2011, 3:79ps13.
• [19]Cohen J: Shots in the dark: the wayward search for an AIDS vaccine. New York: W. W. Norton & Company; 2001.
• [20]Thomas P: Big shot: passion, politics, and the struggle for an AIDS vaccine. New York: Public Affairs; 2001.
• [21]Harris JE: Why we don’t have an HIV vaccine, and how we can develop one. Health Aff (Millwood) 2009, 28:1642-1654.
• [22]Craddock S: Market incentives, human lives, and AIDS vaccines. Soc Sci Med 2007, 64:1042-1056.
• [23]EvaluatePharma. [http://www.evaluatepharma.com webcite]
• [24]Howden LM, Meyer JA: Age and sex composition: 2010. Washington, DC: U.S. Census Bureau; 2011. [2010 Census Briefs]
• [25]Centers for Disease Control and Prevention: Diagnoses of HIV Infection and AIDS in the United States and Dependent Areas, 2010: HIV Surveillance Report, Vol. 22. February 2011. Atlanta, GA: Centers for Disease Control and Prevention; [http://www.cdc.gov/hiv/surveillance/resources/reports/2010report/index.htm webcite]
• [26]Lattanzi M, Rappuoli R: Long-term solutions for the problem of vaccine shortages. Expert Opin Biol Ther 2004, 4:989-992.
• [27]Thompson H: Nature News Blog: United States launches three biodefence centres. London: Nature Publishing Group; [http://blogs.nature.com/news/2012/06/us-launches-three-biodefense-centres.html webcite]